TrialJournal of the International Association of Providers of AIDS Care

Low Incidence and Brief Duration of Gastrointestinal Adverse Events with Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Over 96 Weeks: Post hoc Analyses of AMBER and EMERALD.

Keith Dunn et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.